GAE teo-GFP
(Plasmid
#83958)
-
PurposeCan be used to produce inducible SIV-derived vector. Cells tranduced by lentiviral particles will overexpress GFP upon activation of the tetO promoter.
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 83958 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneLentiviral vector (SIV derived)
-
Vector typeMammalian Expression, Lentiviral
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameTetO-GFP
- Promoter CMV
Cloning Information
- Cloning method Unknown
- 5′ sequencing primer EGFP-N (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Can be used to produce inducible SIV-derived vector. Packaging constructs can be derived from HIV-1 without loss of titer and tranduction efficiencies in cell line. Cells tranduced by lentiviral particles will overexpress GFP upon activation of the tetO promoter. This activation can be ensured by a constitutive expression of the tTA in recipient cells or by addition of tTA-gesicles. Expression of GFP is low without activation, depending on the recipient-cell type.
GFP can be replaced using Age1 and BamH1.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
GAE teo-GFP was a gift from Vincent Lotteau & Philippe Mangeot (Addgene plasmid # 83958 ; http://n2t.net/addgene:83958 ; RRID:Addgene_83958) -
For your References section:
Protein transfer into human cells by VSV-G-induced nanovesicles. Mangeot PE, Dollet S, Girard M, Ciancia C, Joly S, Peschanski M, Lotteau V. Mol Ther. 2011 Sep;19(9):1656-66. doi: 10.1038/mt.2011.138. Epub 2011 Jul 12. 10.1038/mt.2011.138 PubMed 21750535